Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-SA02 as Adjunct Therapy for Staphylococcus Aureus Bacteremia
NCT05184764Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Nov 2024
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 2
01
Overview
A Phase 2 trial of AP-SA02 in Staphylococcus aureus bacteremia (SAB), sponsored by Armata Pharmaceuticals. Started Apr 2022; status: completed.
02
Drugs
AP-SA02
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT05184764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184764.